Iovance Biotherapeutics (IOVA) Gets a Buy from Truist Financial
In a report released today, Asthika Goonewardene from Truist Financial maintained a Buy rating on Iovance Biotherapeutics (IOVA – Research ...
Yahoo Finance21d
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Iovance Biotherapeutics, Inc. SAN CARLOS, Calif., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused ...
ETF Daily News9d
Iovance Biotherapeutics (NASDAQ:IOVA) Trading Down 5.8% Following Analyst Downgrade
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Get Free Report)’s share price dropped 5.8% on Tuesday after Truist Financial lowered their price target on the stock from $25.00 to $15.00.
Yahoo Finance11d
Iovance Biotherapeutics price target lowered to $30 from $34 at Chardan
Chardan lowered the firm’s price target on Iovance Biotherapeutics (IOVA) to $30 from $34 and keeps a Buy rating on the shares. The company reported Q4 results, provided an update on the Amtagvi ...
ETF Daily News11d
Iovance Biotherapeutics (NASDAQ:IOVA) Given New $15.00 Price Target at Truist Financial
Iovance Biotherapeutics (NASDAQ:IOVA – Free Report) had its price objective trimmed by Truist Financial from $25.00 to $15.00 in a research note issued to investors on Monday morning,Benzinga ...
Seeking Alpha14d
Iovance's Q4: Execution Risks Mount As Infusion Growth Slows (Rating Downgrade)
Iovance Biotherapeutics, Inc.'s valuation has halved since August; Amtagvi, its FDA-approved TIL therapy, generated $12.8M in initial revenue, but faces significant risks. Q3 and Q4 performances ...
Yahoo Finance21d
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
SAN CARLOS, Calif., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and ...